Compare ZLAB & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | LMAT |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2017 | 2006 |
| Metric | ZLAB | LMAT |
|---|---|---|
| Price | $25.65 | $79.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $49.60 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 818.3K | 240.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | ★ 38.46 | 30.57 |
| EPS | N/A | ★ 1.42 |
| Revenue | ★ $460,156,000.00 | $249,602,000.00 |
| Revenue This Year | $9.75 | $14.21 |
| Revenue Next Year | $26.03 | $8.88 |
| P/E Ratio | ★ N/A | $55.96 |
| Revenue Growth | ★ 15.33 | 13.53 |
| 52 Week Low | $15.96 | $78.27 |
| 52 Week High | $34.72 | $118.01 |
| Indicator | ZLAB | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 37.39 |
| Support Level | $24.81 | $78.65 |
| Resistance Level | $27.22 | $83.71 |
| Average True Range (ATR) | 0.90 | 1.82 |
| MACD | -0.23 | 0.46 |
| Stochastic Oscillator | 51.30 | 15.69 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.